Cargando…

Fibrinogen-like protein 1 promotes liver-resident memory T-cell exhaustion in hepatocellular carcinoma

BACKGROUND AND AIMS: The key role of tissue-resident memory T (T(RM)) cells in the immune regulation of hepatocellular carcinoma (HCC) has been investigated and reported, but the regulatory mechanism of tumor microenvironment on T(RM) cells is still unclear. Lymphocyte activating gene 3 (LAG-3) is a...

Descripción completa

Detalles Bibliográficos
Autores principales: Yang, Changjie, Qian, Qiwei, Zhao, Yudong, Huang, Bingyuan, Chen, Ruilin, Gong, Qiyu, Ji, Hao, Wang, Chenchen, Xia, Lei, You, Zhengrui, Zhang, Jianjun, Chen, Xiaosong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10040674/
https://www.ncbi.nlm.nih.gov/pubmed/36993960
http://dx.doi.org/10.3389/fimmu.2023.1112672
Descripción
Sumario:BACKGROUND AND AIMS: The key role of tissue-resident memory T (T(RM)) cells in the immune regulation of hepatocellular carcinoma (HCC) has been investigated and reported, but the regulatory mechanism of tumor microenvironment on T(RM) cells is still unclear. Lymphocyte activating gene 3 (LAG-3) is a promising next-generation immune checkpoint that is continuously expressed due to persistent antigen exposure in the tumor microenvironment. Fibrinogen-like protein 1 (FGL1) is a classical ligand of LAG-3 and can promote T cell exhaustion in tumors. Here, we excavated the effect of FGL1-LAG3 regulatory axis on T(RM) cells in HCC. METHODS: The function and phenotype of intrahepatic CD8(+) T(RM) cells in 35 HCC patients were analyzed using multicolor flow cytometry. Using a tissue microarray of 80 HCC patients, we performed the prognosis analysis. Moreover, we investigated the suppressive effect of FGL1 on CD8(+) T(RM) cells both in in vitro induction model and in vivo orthotopic HCC mouse model. RESULTS: There was an increase in LAG3 expression in CD8(+) T(RM) cells in end-stage HCC; moreover, FGL1 levels were negatively correlated with CD103 expression and related to poor outcomes in HCC. Patients with high CD8(+) T(RM) cell proportions have better outcomes, and FGL1-LAG3 binding could lead to the exhaustion of CD8(+) T(RM) cells in tumors, indicating its potential as a target for immune checkpoint therapy of HCC. Increased FGL1 expression in HCC may result in CD8(+) T(RM) cell exhaustion, causing tumor immune escape. CONCLUSIONS: We identified CD8(+)T(RM) cells as a potential immunotherapeutic target and reported the effect of FGL1-LAG3 binding on CD8(+) T(RM) cell function in HCC.